Clinical TrialJul 28, 2026, 07:07 AM
RedHill Updates Opaganib Development for Ebola Outbreak
AI Summary
RedHill Biopharma provided an update on the development of opaganib for Ebola virus disease (EVD) following a substantial increase in Bundibugyo ebolavirus cases and deaths. The company is engaged in discussions with the African Medicines Agency, Ugandan Ministry of Health, and other bodies to finalize development next steps and potential partnerships. Opaganib, an oral SPHK2 inhibitor, has demonstrated a 70.2% mortality reduction in severe COVID-19 patients and showed preclinical efficacy against EVD, including a synergistic effect with remdesivir.
Key Highlights
- Ebola outbreak reported 3,221 cases and 1,407 deaths.
- Opaganib showed 70.2% mortality reduction in severe COVID-19 patients.
- Preclinical studies demonstrated opaganib inhibited EVD in human macrophages.
- Opaganib increased survival rates in one Ebola animal model.
- Synergistic effect observed with remdesivir in preclinical Ebola studies.
- Discussions ongoing with African Medicines Agency and Ugandan Ministry of Health.
- Opaganib is an oral SPHK2 inhibitor with a potential dual mechanism of action.
- BARDA previously selected opaganib for Ebola medical countermeasure development.
Price Impact
More from RDHL